Summary :
Rigel Pharmaceuticals, Inc. Inducement Plan, as amended, with a grant date of January 6, 2022, as an inducement material to the new employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).
Rigel Pharmaceuticals, Inc. today reported the grant of stock options to purchase an aggregate of 610,000 shares of common stock to 14 newly hired employees. These awards were approved by the Compensation Committee of Rigel’s Board of Directors and granted pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, as amended, with a grant date of January 6, 2022, as an inducement material to the new employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
The stock options have an exercise price of $2.62 per share, the price at the close of trading of Rigel’s common stock on January 6, 2022. The stock options awards vest over a four-year period, with one-fourth of the shares subject to such awards vesting on the first anniversary of the award’s vesting commencement date, and the remaining shares vesting in equal monthly installments thereafter.
Rigel is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).
About Rigel
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing, and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer, and rare immune diseases. Rigel’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company’s first FDA-approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients.
Rigel’s other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program, and a receptor-interacting serine/threonine-protein kinase (RIP1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, Rigel has product candidates in development with partners AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.
